Classical and slow-binding inhibitors of human type II arginase

被引:98
|
作者
Colleluori, DM [1 ]
Ash, DE [1 ]
机构
[1] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA
关键词
D O I
10.1021/bi010783g
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Arginases catalyze the hydrolysis of L-arginine to yield L-ornithine and urea. Recent studies indicate that arginases, both the type I and type II isozymes, participate in the regulation of nitric oxide production by modulating the availability of arginine for nitric oxide synthase. Due to the reciprocal regulation between arginase and nitric oxide synthase, arginase inhibitors have therapeutic potential in treating nitric oxide-dependent smooth muscle disorders, such as erectile dysfunction. We demonstrate the competitive inhibition of the mitochondrial human type II arginase by N omega -hydroxy-L-arginine, the intermediate in the reaction catalyzed by nitric oxide synthase, and its analogue N omega -hydroxy-nor-L-arginine, with K-i values of 1.6 muM and 51 nM at pH 7.5, respectively. We also demonstrate the inhibition of human type II arginase by the boronic acid-based transition-state analogues 2(S)-amino-6-boronohexanoic acid (ABH) and S-(2-boronoethyl)-L-cysteine (BEC), which are known inhibitors of type I arginase. At pH 7.5, both ABH and BEC are classical, competitive inhibitors of human type II arginase with Ki values of 0.25 and 0.31 muM, respectively. However, at pH 9.5, ABH and BEC are slow-binding inhibitors of the enzyme with Ki values of 8.5 and 30 nM, respectively. The findings presented here indicate that the design of arginine analogues with uncharged, tetrahedral functional groups will lead to the development of more potent inhibitors of arginases at physiological pH.
引用
收藏
页码:9356 / 9362
页数:7
相关论文
共 50 条
  • [41] Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?
    Raouf, Yasir S.
    Moreno-Yruela, Carlos
    JACS AU, 2024, 4 (11): : 4148 - 4161
  • [42] Slow-Binding Inhibition of Tyrosinase by Ecklonia cava Phlorotannins
    Kim, Jang Hoon
    Lee, Sunggun
    Park, Saerom
    Park, Ji Soo
    Kim, Young Ho
    Yang, Seo Young
    MARINE DRUGS, 2019, 17 (06):
  • [43] Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome
    Hasinoff, Brian B.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2018, 639 : 52 - 58
  • [44] SLOW-BINDING INHIBITION OF CARBOXYLESTERASE AND OTHER SERINE HYDROLASES BY CHLORODIFLUOROACETALDEHYDE
    YIN, HQ
    JONES, JP
    ANDERS, MW
    CHEMICAL RESEARCH IN TOXICOLOGY, 1993, 6 (05) : 630 - 634
  • [45] Expression, purification, and characterization of human type II arginase
    Colleluori, DM
    Morris, SM
    Ash, DE
    FASEB JOURNAL, 2000, 14 (08): : A1555 - A1555
  • [46] Expression, purification, and characterization of human type II arginase
    Colleluori, DM
    Morris, SM
    Ash, DE
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 389 (01) : 135 - 143
  • [47] Cloning and characterization of the human type II arginase gene
    Vockley, JG
    Jenkinson, CP
    Shukla, H
    Kern, RM
    Grody, WW
    Cederbaum, SD
    GENOMICS, 1996, 38 (02) : 118 - 123
  • [48] L-MIMOSINE, A SLOW-BINDING INHIBITOR OF MUSHROOM TYROSINASE
    CABANES, J
    GARCIACANOVAS, F
    TUDELA, J
    LOZANO, JA
    GARCIACARMONA, F
    PHYTOCHEMISTRY, 1987, 26 (04) : 917 - 919
  • [49] Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity
    Moreno-Yruela, Carlos
    Olsen, Christian A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (05): : 779 - 785
  • [50] SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin
    Niehaus, Jason Z.
    Miedel, Mark T.
    Good, Misty
    Wyatt, Allyson N.
    Pak, Stephen C.
    Silverman, Gary A.
    Luke, Cliff J.
    BIOCHEMISTRY, 2015, 54 (45) : 6756 - 6759